2020年8月23日

更多的人才衝到合成生物學金礦:風險資本家葉子羅氏米切爾•穆茨加入密碼子資本8月19日,2020年合成生物學出售4萬億美元bioeconomy鋤頭和鐵鍬,和密碼子資本看到了這個機會。其投資的合成生物學,包括積極進取的獨角獸主生物,Zymergen,螺栓線程,等等。現在,密碼子的資本和其創始人卡爾待價而沽,吸引新的人才。米切爾Mutz-the完成風險投資者,生物技術的企業家,發明家已離開羅氏公司風險資本基金加入密碼子在其總部位於舊金山的辦公室。如果你遵循我的專欄,你知道合成生物學是一個快速增長的領域的前沿製造。它結合了計算、自動化和讀/寫/編輯DNA的能力使可持續發展,高性能的產品,生物學。這包括更好的藥品和診斷Covid-19、智能藥物對癌症和糖尿病,與生物技術和產品我們不喜歡汽車,運動服裝,和手機。加入了密碼子米切爾•穆茨的資本去追求一個簡單的投資理論:偉大的技術團隊,把不可能變為可能。Mutz有第一手經驗在這個行業。在Labcyte他是第一個員工,公司為科研開發革命性的實驗室設備,兩年前退出了一個令人印象深刻的貝克曼庫爾特以3.1億美元的價格出售。 In addition to being Labcyte’s first employee, Mutz also founded Amplyx Pharmaceuticals in 2007, a small molecule therapeutics company that has raised over $140 million in venture financing and recently completed a phase two clinical trial. After three and a half years as senior investment director at Roche Ventures, he’s joining the Codon Capital team , focusing on therapeutics and synthetic biology. With a Ph.D. in chemistry from the University of Rochester, experience working in midsize biotech companies, and 36 issued patents, Mutz sees himself as an investor, serial entrepreneur, and inventor. His expertise and long-time connection to Handelsman make him excited about his new role at Codon Capital. “I’m a huge synthetic biology fan. I’ve been thrilled beyond belief, although we didn’t envision at the time how much Labcyte has become involved with being an engine for synthetic biology,” says Mutz. “I’m very excited to be more active in that space.” Although the economic outlook is a little more uncertain now, Handelsman sees no need to put his foot on the brake. Karl Handelsman, founder of Codon Capital and synthetic biology investor, at SynBioBeta. “Even though it is a time of turmoil, the need for early-stage innovation has never been greater,” says Handelsman. “This is a time when entrepreneurs and investors are stepping up to do even bolder things. It’s a tough time, but it’s a very good time to start things. We need more innovation, and entrepreneurs have a robust desire to build out really important companies.” What does Codon Capital look for in biotech companies? In a challenging technical and economic landscape, Handelsman says Codon Capital’s investment thesis is simple: “We back great technical teams to make the impossible possible.” Mutz and Handelsman are not the only ones who see this young industry’s potential: synthetic biology investment has topped $18 billion over the last ten years . Whether it’s improving humans’ lives, sustaining the planet, or capitalizing on the coming bio-industrial revolution, more and more investors see synthetic biology as the ultimate enabling technology of the triple bottom line . Originally published on Forbes: https://www.forbes.com/sites/johncumbers/2020/08/18/more-talent-rushes-to-the-synthetic-biology-gold-mine-venture-capitalist-mitchell-mutz-leaves-roche-to-join-codon-capital/